Losing track by tracking speckles by Pellicori, Pierpaolo et al.
 
 
 
 
 
 
Pellicori, P., Cleland, J. G.F. and Clark, A. L. (2018) Losing track by 
tracking speckles. JACC: Cardiovascular Imaging, 11(7), pp. 1038-1039. 
(doi:10.1016/j.jcmg.2018.04.027). 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/161343/    
                    
 
 
 
 
 
 
Deposited on: 27 April 2018 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
Losing track by tracking speckles 
Letter to the Editor 
Word count: text: 542, references (5). 
~Pierpaolo Pellicori MD, FESC, ~John GF Cleland MD, FRCP, FESC, FACC, 
*
Andrew L Clark MA, MD, FRCP
 
 
~Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, 
University Avenue, Glasgow, G12 8QQ. 
*Department of Cardiology, Castle Hill Hospital, Hull York Medical School (at 
University of Hull), Kingston upon Hull, HU16 5JQ, UK 
 
 
Corresponding author: Dr Pierpaolo Pellicori 
Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, 
University Avenue, Glasgow, G12 8QQ, UK. 
Tel: +44 0 141 330 4744; Fax: +44 0 141 330 5094 
Email: pierpaolo.pellicori@glasgow.ac.uk 
 
Conflict of interest: none 
 
Inclusion of patients whose symptoms are not due to left ventricular dysfunction has 
undoubtedly contributed to the neutral outcome of many trials of heart failure with preserved 
ejection fraction (HFpEF). Exertional breathlessness is common in older people. Many are 
empirically prescribed a loop diuretic in an attempt to relieve symptoms, often without 
further investigation. This may obscure a diagnosis of HFpEF (1). Obesity, or common 
problems in older age, such as chronic lung or joint disease, might provoke symptoms during 
exercise. Decreased activity levels will reduce skeletal muscle function, complicating the 
interpretation of symptoms and clinical investigations. 
 
In landmark trials, natriuretic peptides have consistently been the strongest predictor of 
outcome and therefore, if HFpEF is considered a disease that has serious consequences, must 
be considered a key diagnostic test (2). 
 
We congratulate Mordi and colleagues (3) on their study on patients, with either HFpEF 
(n=62) or hypertension (n=22), and 28 healthy controls. All subjects underwent 
cardiopulmonary exercise, very detailed echocardiography and cardiac magnetic resonance 
imaging (cMRI).  Two major findings were reported: firstly, global longitudinal strain (GLS) 
by speckle tracking worsens as the disease progresses from healthy individuals, to overt 
HFpEF (4). By contrast, other echocardiographic measurements, such as E/E’ (endorsed by 
guidelines and used in clinical practice to diagnose HFpEF (5)), did not. Secondly, 
myocardial extracellular volume (ECV) measured by cMRI best discriminates amongst the 
three populations, leading the authors to suggest a potential role for ECV as an inclusion 
criterion and surrogate endpoint in clinical trials of HFpEF. 
 
We have several concerns about the populations studied. In a large proportion of those 
thought to have HFpEF, cardiac dysfunction was likely not to be the primary cause of their 
symptoms: their median BNP was only 52 ng/L, and more than a quarter had BNP levels 
below 35 ng/L, a cut-off recommended by European Society of Cardiology (5) to exclude 
serious cardiac dysfunction. Moreover, despite the inclusion of a group of people with severe 
exercise intolerance diagnosed as having heart failure, fewer than 50% were prescribed a loop 
diuretic. By comparison, a loop diuretic was prescribed to more than a third of the patients 
with hypertension despite a lack of recommendation from guidelines; perhaps loop diuretics 
were masking the presence of HFpEF. Finally, 25% of healthy controls supposed to have 
“normal” BNP, had a BNP>35 ng/L, which would have qualified them for a diagnosis of 
HFpEF if they had reported breathlessness at any point. There was thus substantial overlap 
between the three groups of subject.  
 
Baseline cardiac rhythm was also not reported: we suspect that all patients enrolled in that 
study were in sinus rhythm. Although sinus rhythm might be the norm for studies in 
hypertension, it is highly unusual for patients with HFpEF, amongst whom at least a third is 
expected to have permanent atrial fibrillation (4, 5). The authors stated that left atrial dilation 
was one of the key criteria used to diagnose HFpEF, but left atrial dimensions were not 
reported.  
 
Future studies might confirm that GLS and ECV are useful diagnostic tools to track patient’s 
journey from asymptomatic to overt HF, and may help unravel the complex pathophysiology 
of HFpEF. However, a common international diagnostic standard is required and this must 
include, in the current state of knowledge, natriuretic peptides.    
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